loader
Please Wait
Applying Filters...

Quotient Sciences Quotient Sciences

X

Technical details about Raloxifene Hydrochloride, learn more about the structure, uses, toxicity, action, side effects and more

Client Email Product
Menu
2D Structure
Also known as: 82640-04-8, Raloxifene hcl, Evista, Keoxifene hydrochloride, Keoxifene, Optruma
Molecular Formula
C28H28ClNO4S
Molecular Weight
510.0  g/mol
InChI Key
BKXVVCILCIUCLG-UHFFFAOYSA-N
FDA UNII
4F86W47BR6

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;hydrochloride
2.1.2 InChI
InChI=1S/C28H27NO4S.ClH/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29;/h4-13,18,30-31H,1-3,14-17H2;1H
2.1.3 InChI Key
BKXVVCILCIUCLG-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O.Cl
2.2 Other Identifiers
2.2.1 UNII
4F86W47BR6
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Evista

2. Keoxifene

3. Keoxifene Hydrochloride

4. Ly 139481

5. Ly 156758

6. Ly-139481

7. Ly-156758

8. Ly139481

9. Ly156758

10. Raloxifene

11. Raloxifene Hcl

2.3.2 Depositor-Supplied Synonyms

1. 82640-04-8

2. Raloxifene Hcl

3. Evista

4. Keoxifene Hydrochloride

5. Keoxifene

6. Optruma

7. Raloxifene Teva

8. (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone Hydrochloride

9. Raloxifene (hydrochloride)

10. Ly 156758

11. Ly156758

12. Ly-156758

13. Nsc-706725

14. 2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol Hydrochloride

15. Chebi:50740

16. Evista (raloxifene Hydrochloride)

17. 4f86w47br6

18. 6-hydroxy-2-(p-hydroxyphenyl)benzo(b)thien-3-yl-p-(2-piperidinoethoxy)phenyl Ketone, Hydrochloride

19. Dsstox_cid_14181

20. Dsstox_rid_79119

21. Dsstox_gsid_34181

22. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride

23. [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(2-piperidin-1-ylethoxy)phenyl]methanone;hydrochloride

24. Smr000058508

25. Raloxifene Hydrochloride [usan]

26. Ncgc00015889-05

27. Cas-82640-04-8

28. C28h27no4s.hcl

29. Loxifen

30. Unii-4f86w47br6

31. Sr-01000076102

32. Cdt-raloxifene

33. Raloxifene-d4 Hcl

34. Raloxifene Cloridrato

35. Evista (tn)

36. Mfcd01938233

37. Prestwick_1035

38. Raloxifene Hydrochloride [usan:usp]

39. Methanone, Hydrochloride

40. Cloridrato De Raloxifeno

41. Clorhidrato De Raloxifeno

42. Chlorhydrate De Raloxifene

43. Ly139481 Hydrochloride

44. Ly156758 Hydrochloride

45. Chembl1116

46. Schembl19077

47. Mls000859902

48. Mls001332533

49. Mls001332534

50. Mls002222293

51. Raloxifene Hydrochloride, Solid

52. Evista, Raloxifene Hydrochloride

53. Raloxifene Hydrochloride- Bio-x

54. Dtxsid1034181

55. Ly156758 (keoxifene) Hcl

56. Ly-139481 Hcl

57. Hms1570n05

58. Pharmakon1600-01505622

59. Amy23426

60. Bcp05713

61. Raloxifene Hydrochloride (jan/usp)

62. Tox21_110255

63. Tox21_302369

64. Tox21_501051

65. Hy-13738a

66. Nsc706725

67. Nsc759285

68. Raloxifene Hydrochloride [mi]

69. S1227

70. Raloxifene Hydrochloride [jan]

71. Akos008131940

72. Tox21_110255_1

73. Ac-8390

74. Ccg-213497

75. Cs-1775

76. Ds-2162

77. Ks-1102

78. Lp01051

79. Nc00665

80. Nsc 706725

81. Nsc 759285

82. Nsc-759285

83. Raloxifene Hydrochloride [mart.]

84. Raloxifene Hydrochloride [vandf]

85. Ncgc00015889-03

86. Ncgc00015889-11

87. Ncgc00092353-01

88. Ncgc00092353-03

89. Ncgc00094334-01

90. Ncgc00094334-02

91. Ncgc00255153-01

92. Ncgc00261736-01

93. Raloxifene Hydrochloride [usp-rs]

94. Raloxifene Hydrochloride [who-dd]

95. Br164310

96. Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-, Hydrochloride

97. Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride (1:1)

98. Raloxifene Hydrochloride [ema Epar]

99. Eu-0101051

100. Ft-0630912

101. R0109

102. Sw197106-5

103. En300-52517

104. Raloxifene Hydrochloride [orange Book]

105. D02217

106. R 1402

107. Raloxifene Hydrochloride [ep Monograph]

108. Raloxifene Hydrochloride [usp Impurity]

109. Raloxifene Hydrochloride [usp Monograph]

110. 640r048

111. A840401

112. Q-201656

113. Sr-01000076102-2

114. Sr-01000076102-9

115. Q27122215

116. (6-oxo-1,6-dihydro-pyridazin-3-yloxy)-aceticacid

117. Raloxifene Hydrochloride, European Pharmacopoeia (ep) Reference Standard

118. Raloxifene Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

119. Raloxifene Hydrochloride, United States Pharmacopeia (usp) Reference Standard

120. (6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)-(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanone Hydrochloride

121. (6-oh-2-(4-oh-ph)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)ph)methanone Hydrochloride

122. [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl][4-(2-piperidin-1-ylethoxy)phenyl]methanone Hydrochloride

123. [6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride

124. [6-hydroxy-2-(4-hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride

125. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone Hydrochloride

126. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone, Monohydrochloride

127. [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride

128. [6-hydroxy-2[4-hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride

129. [6-hydroxy-2[4-hydroxyphenyl)benzo [b]thien3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride

130. [6-hydroxy-2[4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride

131. 1-[2-(4-{[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]carbonyl}phenoxy)ethyl]piperidinium Chloride

132. 6-hydroxy-2-(4-hydroxyphenyl)-3-[ 4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, Hydrochloride

133. 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]-thiophene Hydrochloride

134. 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene Hydrochloride

135. 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl Methanone Hydrochloride

136. 6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl 4-[2-(1-piperidinyl)ethoxy]phenyl Ketone Hydrochloride

137. 6-hydroxy-2-(p-hydroxyphenyl)benzo(.beta.)thien-3-yl-p-(2-piperidinoethoxy)phenyl Ketone, Hydrochloride

138. Methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(.beta.)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)-, Hydrochloride

139. Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, Hydrochloride (1:1)

140. Raloxifene Hydrochloride For Peak Identification, European Pharmacopoeia (ep) Reference Standard

2.4 Create Date
2005-03-26
3 Chemical and Physical Properties
Molecular Weight 510.0 g/mol
Molecular Formula C28H28ClNO4S
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count7
Exact Mass509.1427572 g/mol
Monoisotopic Mass509.1427572 g/mol
Topological Polar Surface Area98.2 Ų
Heavy Atom Count35
Formal Charge0
Complexity655
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 4  
Drug NameEvista
PubMed HealthRaloxifene (By mouth)
Drug ClassesAntineoplastic Agent, Endocrine-Metabolic Agent
Drug LabelEVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m...
Active IngredientRaloxifene hydrochloride
Dosage FormTablet
Routeoral; Oral
Strength60mg
Market StatusPrescription
CompanyLilly

2 of 4  
Drug NameRaloxifene hydrochloride
Drug LabelEVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m...
Active IngredientRaloxifene hydrochloride
Dosage FormTablet
Routeoral; Oral
Strength60mg
Market StatusTentative Approval; Prescription
CompanyTeva Pharms Usa; Invagen Pharms; Watson Labs

3 of 4  
Drug NameEvista
PubMed HealthRaloxifene (By mouth)
Drug ClassesAntineoplastic Agent, Endocrine-Metabolic Agent
Drug LabelEVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m...
Active IngredientRaloxifene hydrochloride
Dosage FormTablet
Routeoral; Oral
Strength60mg
Market StatusPrescription
CompanyLilly

4 of 4  
Drug NameRaloxifene hydrochloride
Drug LabelEVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds. The chemical structure is:The chemical designation is m...
Active IngredientRaloxifene hydrochloride
Dosage FormTablet
Routeoral; Oral
Strength60mg
Market StatusTentative Approval; Prescription
CompanyTeva Pharms Usa; Invagen Pharms; Watson Labs

4.2 Drug Indication

Optruma is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5. 1).


Evista is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.


Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.

When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Selective Estrogen Receptor Modulators

A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63) (See all compounds classified as Selective Estrogen Receptor Modulators.)


Bone Density Conservation Agents

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)


Estrogen Antagonists

Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Selective Estrogen Receptor Modulators [MoA]; Estrogen Agonist/Antagonist [EPC]
5.3 ATC Code

G03XC01


G03XC01


G03XC01


Post Enquiry
POST ENQUIRY